OLDWICK, N.J., Aug. 3, 2020 /PRNewswire/ -- Provention Bio,
Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced the appointment of Heidy Abreu
King-Jones to the newly created role of Chief Legal Officer.
Ms. King-Jones brings nearly 12 years of corporate counsel and law
firm experience in the biotechnology and pharmaceutical
sectors.
"As Provention prepares to transition to a commercial business,
we are committed to upholding the best practices of compliance,
corporate governance, and enterprise risk management across all
areas of our organization," stated Ashleigh Palmer, CEO of
Provention Bio. "Heidy's experience in developing compliance
programs for rare disease launches and working with companies'
patient advocacy and commercial teams will be invaluable as we
continue to advance PRV-031 (teplizumab) toward the market.
We welcome Heidy to the team and look forward to her
contributions."
"I am impressed with the tremendous progress Provention has
achieved since its founding, especially in the last year. I look
forward to working with the executive team to support the Company's
growth and commercial readiness activities for teplizumab for the
delay or prevention of insulin-dependent type 1 diabetes in
presymptomatic patients," stated Ms. King-Jones.
Ms. King-Jones most recently served as Senior Vice President,
General Counsel and Corporate Secretary at Axcella Health.
She joined Axcella Health in 2018 as Senior Vice President, General
Counsel and Corporate Secretary where she was responsible for
Axcella's corporate legal function and strategy. From 2013 to 2018,
she held positions of increasing responsibility in the legal
department at Sarepta Therapeutics, most recently serving as Senior
Director, Corporate Law. While at Sarepta, she served as a
member of the Company's commercial readiness working group and was
responsible for the development of the compliance program, contract
and other legal work for the launch of its first product, Exondys
51TM.
Ms. King-Jones began her legal career in the Securities &
Public Companies Practice Group at Ropes & Gray LLP, where she
represented private and publicly traded companies in the
pharmaceutical, utility and technology industries. Ms.
King-Jones holds a J.D. and LL.M in International and Comparative
Law from Cornell Law School, and a
B.A. from Dartmouth College.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company leveraging a transformational drug development strategy
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to source, transform and develop
therapeutic candidates targeting the high morbidity, mortality and
escalating costs of autoimmune diseases. Provention's diversified
portfolio includes teplizumab, a pre-commercial-stage candidate
that has been shown to delay the onset of insulin-dependent type 1
diabetes (T1D) in at-risk patients during the presymptomatic phase
of the disease. The Company's portfolio includes additional
clinical product development candidates that have demonstrated
proof-of-mechanism and/or proof-of-concept in other autoimmune
diseases, including celiac disease and lupus.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to, statements relating to the
Company's studies. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimate," "expect," and "intend," among others. These
forward-looking statements are based on Provention's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
failure to obtain FDA approvals or clearances and noncompliance
with FDA regulations; uncertainties of patent protection and
litigation; dependence upon third parties; substantial
competition; our need for additional financing and the risks listed
under "Risk Factors" in our annual report on Form 10-K for the year
ended December 31, 2019 and any subsequent filings with
the Securities and Exchange Commission. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval and commercialization of new products.
Provention does not undertake an obligation to update or revise any
forward-looking statement. The information set forth herein speaks
only as of the date hereof.
Investor Contact:
Sam
Martin, Argot Partners
Sam@argotpartners.com
212-600-1902
Media Contact:
Lori
Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-appoints-heidy-abreu-king-jones-as-chief-legal-officer-301104931.html
SOURCE Provention Bio, Inc.